SELLAS Life Sciences (SLS) Other Non-Current Liabilities (2011 - 2022)

SELLAS Life Sciences (SLS) has 12 years of Other Non-Current Liabilities data on file, last reported at $170000.0 in Q3 2022.

• Quarterly Other Non-Current Liabilities fell 96.62% year-over-year to $170000.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $170000.0 (down 96.62% YoY) and the FY2021 annual result came in at $296000.0, down 93.61% from the prior year.
• Other Non-Current Liabilities retreated to $170000.0 in Q3 2022 per SLS's latest filing, from $181000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $5.3 million in Q3 2018 and bottomed at $170000.0 in Q3 2022.
• The 5-year median for Other Non-Current Liabilities is $4.8 million (2019), against an average of $3.9 million.
• The widest annual swing landed in 2018, when Other Non-Current Liabilities jumped 320.29%; it then slumped 96.62% in 2022.
• Tracing SLS's Other Non-Current Liabilities over 5 years: stood at $4.3 million in 2018, then increased by 13.55% to $4.9 million in 2019, then slipped by 5.68% to $4.6 million in 2020, then tumbled by 93.61% to $296000.0 in 2021, then tumbled by 42.57% to $170000.0 in 2022.
• Per Business Quant, the three latest SLS Other Non-Current Liabilities figures stand at $170000.0 (Q3 2022), $181000.0 (Q2 2022), and $296000.0 (Q1 2022).

Peer Comparison